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Abstract
With the introduction of hormonal substitution therapy in the 1950s, adrenal insufficiency (AI) has been turned into 
a manageable disease in pregnant women. In fact, in the light of glucocorticoid replacement therapy and improved 
obstetric care, it is realistic to expect good maternal and fetal outcomes in patients with AI. However, there are still 
a number of challenges such as establishing the diagnosis of AI in pregnant women and optimizing the treatment of 
AI and related comorbidities prior to as well as during pregnancy. Clinical and biochemical diagnoses of a new-onset 
AI may be challenging because of overlapping symptoms of normal pregnancy as well as pregnancy-induced changes 
in cortisol values. Physiological changes occurring during pregnancy should be taken into account while adjusting the 
substitution therapy. The high proportion of reported adrenal crisis in pregnant women with AI highlights persistent 
problems in this particular clinical situation. Due to the rarity of the disease, there is no prospective data-guiding 
management of pregnancy in patients with known AI. The aim of this review is to summarize the maternal and fetal 
outcomes based on recently published case reports in patients with AI and to suggest a practical approach to diagnose 
and manage AI in pregnancy.
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Background and epidemiology
Adrenal insufficiency (AI) can either be caused by 
destruction of the adrenal glands through different 
mechanisms with glucocorticoid, mineralocorticoid 
and/or androgen deficiencies (primary AI), or may 
occur as a result of dysfunction of the pituitary with 
adrenocorticotropic hormone (ACTH) deficiency 
(secondary AI) or of the hypothalamus with corticotropin-
releasing hormone (CRH) deficiency (tertiary AI). In 
developed countries, autoimmune adrenalitis is the 
most common cause of primary AI, which may occur 
in isolation or as part of an autoimmune polyglandular 
syndrome (APS). APS type 2 is the most common form 
presented as a combination of Addison’s disease, thyroid 
autoimmune disease, type 1 diabetes and/or premature 
ovarian failure. Type 1 and type 4 APS may also present 
with primary AI. In developing countries, tuberculosis 
with the involvement of the adrenal glands is still 
more common than autoimmune adrenalitis as a cause 
Published by Bioscientifica Ltd.
Printed in Great Britain
© 2018 European Society of Endocrinology
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
178:2 R46Review G Anand and F Beuschlein Pregnancy and adrenal 
insufficiency
www.eje-online.org
of primary AI. Other causes include fungal infections, 
adrenal hemorrhage, metastases or infarction involving 
both adrenal glands. Congenital adrenal hyperplasia 
as another cause of primary AI will not be discussed in 
this review.
Prolonged exogenous glucocorticoid administration 
for various conditions (such as asthma, rheumatoid 
arthritis and inflammatory bowel disease, among others) 
is the most common cause of combined secondary and 
tertiary AIs due to impaired ACTH and CRH secretion. 
Other pregnancy-related causes of secondary AI are 
Sheehan’s syndrome (due to postpartum pituitary necrosis) 
and lymphocytic hypophysitis occurring preferentially in 
postpartum setting or in the last trimester. A structural 
disease of the pituitary as a cause of secondary AI is 
mostly known and treated before conception. Similarly, 
all patients with bilateral adrenalectomy due to Cushing 
syndrome (CS), or with unilateral adrenalectomy due to 
a benign or malignant adrenal tumor, and after cranial 
radiotherapy, most likely have an established endocrine 
follow-up and optimal glucocorticoid replacement 
therapy where needed.
Although AI is very rare in pregnancy, yet it can lead to 
significant maternal and fetal morbidities if the diagnosis 
is missed during pregnancy or in the puerperium. In fact, 
prior to the introduction of glucocorticoid replacement 
therapy, Addison’s disease was associated with a high 
maternal mortality (35–45%), so that women were strongly 
discouraged from becoming pregnant (1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 11). Modern glucocorticoid replacement therapy 
and improved obstetric care have both contributed 
immensely in reducing maternal as well as fetal morbidity 
and mortality. Nowadays, an uneventful pregnancy with 
good maternal and fetal outcomes can be expected in the 
majority of patients with known AI (1, 2, 3, 4, 5, 6, 7, 8, 
9, 10, 11, 12).
The exact prevalence of AI in pregnancy is 
unknown. Schneiderman and coworkers reported the 
incidence of primary AI to be 1 in 3000 pregnancies in 
a population-based cohort study on 7.7 million births 
with an observed increase in prevalence of Addison’s 
disease from 5.6 per 100 000 in 2003 to 9.6 per 100 
000 in 2011 (13). In the literature (as summarized in 
Table  1), the underlying reasons for AI in pregnant 
patients are evenly distributed between primary 
(44%) and secondary (45%) causes, which also defines 
the presence of potential hormonal comorbidities. 
The most commonly reported coexisting endocrine 
disorders are hypothyroidism (50%) and a few cases of 
type 1 diabetes, among others.
Effects of the feto–placental unit on 
steroid metabolism
The feto-placental unit is actively controlling the steroid 
milieu of the fetus. Additionally, it is responsible for 
various changes in the maternal hypothalamic pituitary 
adrenal (HPA) axis leading to a state of physiological 
hypercortisolism in pregnancy (1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12).
In healthy pregnant women, total and free plasma 
cortisol, ACTH, CRH, cortisol-binding globulin (CBG) and 
urinary-free cortisol increase (13, 14, 15, 16). The placenta 
can itself produce biologically active CRH and ACTH 
stimulating the maternal pituitary and adrenal glands, 
respectively. CBG increases 3–4-fold following estrogen 
stimulation, thereby not only increasing the half-life of 
cortisol but also increasing total plasma cortisol values. 
Free cortisol increases by the 11th  week of gestation. 
In contrast to CS, circadian rhythmicity is maintained 
throughout pregnancy implying an altered set point of 
the HPA axis and a relative tissue refractoriness to the 
effects of cortisol in pregnancy (13, 14, 15, 17).
Similarly, the activity of the renin–angiotensin–
aldosterone system is increased by the 8th  week of 
gestation. On the other hand, progesterone exerts anti-
mineralocorticoid effects and results in a decrease in 
systemic vascular resistance. As a combined effect of these 
mechanisms, there is a net volume expansion during 
pregnancy (14).
Up to the 33rd  week of gestation, 90–95% of fetal 
cortisol is derived from maternal adrenal secretion; 
thereafter, fetal adrenal cortisol production progressively 
increases with decreased maternal contribution. In cases 
of unrecognized maternal AI, transplacental passage of 
cortisol from the fetus to the mother might have a partial 
protective effect during the last trimester. On the other 
hand, the fetus is relatively protected from excessive 
hydrocortisone by the placental 11-β hydroxysteroid 
dehydrogenase 2 even in women receiving supra-
physiological doses of glucocorticoid treatment (5).
Fertility and preconceptional considerations
In the majority of cases (75.8%; Table 1), AI is present and 
known well before pregnancy. Therefore, there are specific 
considerations to be taken into account before planning a 
pregnancy such as optimizing the glucocorticoid treatment 
and screening for comorbidities to optimize chances of 
conception. Erichsen and colleagues performed a survey 
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in 269 females of the Norwegian Addison’s registry with 
174 women (65%) participating in the survey. The author 
found a decreased standardized incidence ratio of 0.69 
for birth (confidence interval, 0.52–0.86) as a proof of 
reduced fertility in females with Addison’s disease after 
excluding women with premature ovarian insufficiency 
(18). In untreated patients with primary AI, fertility can be 
reduced due to decreased generalized sense of well-being 
and reduced libido due to the lack of androgens among 
other mechanisms. Despite androgen depletion, impaired 
sexuality had not been reported in the mentioned study 
(18) and a common reason for sexual inactivity – the lack 
of a partner – has also to be considered.
Coexisting autoimmune disorders such as thyroid 
disease and premature ovarian insufficiency are other 
reasons for reduced fertility in patients with primary AI. 
Similarly, a common cause of reduced fertility in patients 
with pituitary disease is altered gonadotropin secretion. 
Overall, concomitant hormonal deficiencies should be 
addressed to enable conception in a patient with known 
AI as fertility may in fact be mainly reduced due to these 
hormonal deficits. For example, patients with complete 
loss of pituitary function need assistance of artificial 
reproductive techniques to conceive. These pregnancies 
are considered as high-risk (19, 20).
In addition to issues of fertility, a main focus of 
preconception endocrine counseling should be patient 
education regarding the need of treatment adjustment 
during gestation, especially during stress states. Also, 
the obstetrician should be informed regarding the need 
of adjustment of glucocorticoid dose in stress situations 
such as infections, hyperemesis and delivery. In fact, as 
discussed below, delivery can be considered as one of 
the most stressful situations, where use of an established 
protocol of parenteral stress dose glucocorticoid 
application could help in assuring optimal management.
Establishing the diagnosis of a new-onset 
AI during pregnancy
In general, the slowly progressive course of AI makes 
early diagnosis challenging. It is believed that more than 
90% of the cells of adrenal cortex are destroyed before 
clinical manifestations of primary AI become apparent 
(21). Pregnancy can mirror some of the symptoms of 
AI and a biochemical diagnosis of a mild AI may be 
particularly challenging due to physiological state of 
hypercortisolism. Therefore, it is prudent to include 
AI in the differential diagnosis in patients presenting 
with excessive fatigue, malaise, weight loss, vomiting, 
dizziness, hyperpigmentation, abdominal pain and/
or electrolyte disturbances. Clinical suspicion should 
be particularly high in patients with personal or family 
history of an autoimmune disease (16). In contrast to 
chloasma of pregnancy, hyperpigmentation of Addison’s 
disease involves non-exposed parts of skin/creases of 
hands, extensor surfaces and mucous membranes. Salt 
craving, hyponatremia with more than 5 mmol/L decrease 
in plasma sodium and metabolic acidosis are other 
specific clues for AI. As expected and according to the 
reviewed literature (Table 1), onset of AI within pregnancy 
accounts for only a minority of patients (17.7%) with 
even distribution over the duration of the pregnancy 
(first trimester; 8.1%, second trimester; 4.8% and third 
trimester; 4.8%, respectively).
Acute presentation can occur with adrenal crisis 
in stressful situations encountered in early pregnancy 
(hyperemesis gravidarum), infections during pregnancy/
puerperium, operations or delivery (both vaginal 
and cesarean). In the case of severe AI, it is of utmost 
importance to initiate treatment with hydrocortisone 
before awaiting results of laboratory tests and testing 
can even be postponed until stabilization of the patient’s 
condition. In the event of obstetric hemorrhage where 
tachycardia and hypotension persist after adequate 
replacement of blood products, the possibility of acute 
Sheehan’s syndrome should be kept in mind and minimal 
investigation including baseline levels of ACTH, cortisol, 
prolactin and free thyroxine should be undertaken.
Currently, paired measurement of early morning 
cortisol and ACTH is recommended as screening 
investigation to diagnose primary AI. A low early 
morning cortisol <5 µg/dL in the setting of typical 
clinical symptoms is sufficient to confirm the diagnosis 
of AI and when accompanied with raised ACTH levels 
(>2-fold the upper limit of reference range) also establishes 
its cause to be primary AI. In equivocal cases with early 
morning cortisol between 5 and 32 µg/dL depending 
on the trimester, it is safe to employ the corticotropin 
stimulation test as diagnostic ‘gold standard’ (5). Suri and 
coworkers demonstrated higher peak cortisol responses of 
up to 36 µg/dL to 250 µg/dL of cosyntropin in 36 healthy 
pregnant women in the second and third trimesters. As a 
result, many authors suggest the use of trimester-specific 
cut-offs for stimulated cortisol values in the first, second 
and third trimesters of 25, 29 and 32 µg/dL, respectively, 
to diagnose or exclude AI (3, 6, 12, 17). Additionally, 
validated antibody assays should be used as adjuvant tests 
as 21-hydroxylase antibodies are positive in >90% of the 
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patients and 17-hydroxylase antibodies in 30% of the 
patients with primary AI (22).
In cases with recent onset of secondary AI, 
corticotropin stimulation tests may give misleading 
results as adrenals may still respond normally to 
exogenous ACTH. However, insulin hypoglycemia testing 
is contraindicated in pregnancy due to safety reasons. 
Suri proposed the use of salivary cortisol as a more 
physiological measure of adrenal reserve in pregnancy 
(23) but it remains a challenge to diagnose or exclude AI 
based on these measures only. Fortunately, a new-onset 
secondary AI due to a structural disease of pituitary is very 
rare in pregnancy. These patients may also have additional 
symptoms such as headache or visual disturbances due to 
mass effects of a pituitary tumor. However, lymphocytic 
hypophysitis might present preferentially in the last 
trimester or postpartum. While treatment of secondary AI 
and secondary hypothyroidism is of particular importance 
during pregnancy, imaging can be delayed until delivery 
in patients without symptoms of mass effect. In the case of 
need to evaluate visual symptoms, MRI without contrast 
should be used in pregnant patients.
Substitution and dosage adjustment 
during pregnancy
The main aim of substitution therapy is to avoid both 
under- and over-replacement of glucocorticoid and 
mineralocorticoid treatments and to prevent adrenal crisis. 
Undesirable effects of over-replacement are increased 
risk of gestational diabetes, hypertension/preeclampsia, 
weight gain and bruising. In contrast, low substitution 
dosages might increase the risk of hyperemesis and put 
the patients at risk to develop an acute adrenal crisis.
Hydrocortisone has been advocated as the glucocorticoid 
substitution of choice. Accordingly, in the majority of 
reported cases in the literature, hydrocortisone is used (in 
78.4% either alone or in combination with fludrocortisone; 
Table 1). High-dose glucocorticoid treatment is considered 
teratogenic in rodents causing cleft palate, fetal death and 
placental degeneration (24). In contrast, hydrocortisone 
exposure in humans is considered safe probably because 
of different glucocorticoid receptor–ligand systems and 
because of placental 11-β-hydroxysteroid dehydrogenase 
type 2 inactivating cortisol.
Figure 1
Overview on diagnostic and therapeutic considerations in patients with newly diagnosed or known adrenal insufficiency (AI).
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Based on the physiological increase in total and free 
cortisol values in normal pregnancy, the current approach 
is to increase hydrocortisone doses up to 20–40% in the 
last trimester (3). Due to the lack of sufficient evidence, 
patients should have clinical follow-up once every 
trimester with dosage adaptation based on the individual 
course of pregnancy as illustrated in the flow diagram 
(Fig.  1). Labor is a state of increased glucocorticoid 
requirement and should be preferably managed with 
hydrocortisone stress dose (100 mg hydrocortisone 
intravenously) followed by a continuous infusion of 100–
200 mg/24 h at the beginning of the second stage of labor 
(3, 4, 5, 6). Similarly, hydrocortisone stress dose can be 
given as premedication followed by a continuous infusion 
of 100–200 mg/24 h in case of cesarean section. We suggest 
stepwise reduction of hydrocortisone supplementation 
therapy after the stress phase of delivery has passed. The 
duration of this transition period is mostly 24–48 h after 
delivery but may vary in individual cases.
Fludrocortisone is mostly used as a mineralocorticoid 
replacement in Addison’s disease. In fact, mineralocorticoid 
requirement may slightly increase in the last trimester due 
to anti-mineralocorticoid effects of progesterone. Clinical 
parameters such as signs of orthostatic hypotension 
and increase in serum potassium should govern dose 
adjustment. Likewise, fludrocortisone must be reduced 
in cases of hypertension and or hypokalemia and even 
be withdrawn in cases of preeclampsia. In contrast, 
plasma renin cannot be used as a reliable marker to adjust 
mineralocorticoid dosing in pregnancy.
Management of adrenal crisis
As there had been no clear definition of adrenal crisis, in 
2015 Allolio proposed a definition of adrenal crisis as a 
profound impairment of general health and the presence 
of at least two of the following signs or symptoms: 
hypotension (systolic blood pressure <100 mmHg), nausea 
or vomiting, severe fatigue, hyponatremia, hypoglycemia 
and hyperkalemia, making subsequent parenteral 
glucocorticoid administration necessary (25). According 
to the current literature search, a high incidence of adrenal 
crisis in pregnant women with AI of 69% can be assumed 
(Table  1) despite the fact that this clear definition had 
not been met in all cases. Although this percentage could 
also be an overestimation due to general over-reporting 
and due to the initial clinical presentation of newly 
diagnosed patients, adrenal crisis remains a clinically 
relevant problem. The probable triggers of adrenal crisis 
during pregnancy are hyperemesis, infections and non-
adherence to substitution therapy.
Patient and partner education to adjust the 
hydrocortisone dosage in stressful situations and 
instruction to self-inject hydrocortisone are important 
measures to prevent an impending adrenal crisis. The 
main aims for the treatment of adrenal crisis are to treat 
hypotension with rapid fluid replacement and to reverse 
glucocorticoid deficiency with parenteral hydrocortisone 
(12). These aims also apply to pregnant women with 
additional attention to fetal monitoring to assure the 
well-being of the unborn child.
Outcome of pregnancies in AI
In the recent literature, there is no report of maternal death 
with a direct relation to the presence of AI (Table 1). In 
contrast, unfavorable outcomes of pregnancies have been 
described with intrauterine growth retardation (IUGR) 
being the most common (4.2%; Table 1). In an analysis 
of 31 pregnancies in 27 women with hypopituitarism of 
different etiologies, the rate of children who were small 
for gestational age was found to be higher (38% vs 12.7% 
in IVF control pregnancies) (20). As a potential cause, 
poor placental function was proposed in these women. In 
addition to growth retardation, there were more cesarean 
deliveries (89% vs 11.4%), more transverse lies (15% vs 
2.1%) and more postpartum hemorrhages (5.26% vs 
1%) (20). High rate of cesarean section was partly due to 
more malpresentations and partly due to obstetrician’s 
recommendation.
Gradden and colleagues reported on an abortion in the 
11th week of pregnancy in a previously unknown case of 
primary AI, where the diagnosis was delayed as symptoms 
were initially thought to be related to hyperemesis 
of pregnancy (26). Furthermore, Otta and coworkers 
described one case of neonatal death from a mother with 
known primary AI occurring 20 h after birth due to acute 
cardiorespiratory failure (27). In this case, the patient 
was reported to be non-adherent to the recommended 
glucocorticoid treatment throughout the gestation period. 
In addition, Seaward and colleagues reported on two 
pregnancies in a patient, where stillbirth occurred in the 
first pregnancy at 31st week of gestation due to placental 
disruption (28). In this case, the patient also suffered from 
adrenal crisis before delivery, while the course of a second 
pregnancy was uneventful.
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Lactation in the context of AI
Lactation can itself be affected by comorbidities of 
AI including pituitary insufficiency. Matsuzaki and 
colleagues compiled 21 cases of acute Sheehan’s syndrome 
from the literature (1990–2014) and included his own 
rare case of a successful second pregnancy after induction 
of ovulation in a patient with Sheehan’s syndrome 
under replacement treatment with hydrocortisone and 
thyroxine (Table 1 describes only his case). The authors 
reported variable onset of symptoms of different pituitary 
hormonal deficiencies with a median time of presentation 
of secondary AI being 7.9 days following delivery (29).
Given the ability as well as willingness of breastfeeding 
in patients with AI, the question arises, whether 
glucocorticoid substitution could potentially affect the 
child. In 1975, McKenzie and colleagues reported negligible 
excretion of prednisolone in breast milk over a period of 
48 h after receiving 5 mg of 3H-prednisolone (range: 0.07–
0.23% of the dose/L of milk/day). The authors concluded 
that the exposure of the suckling infant through the breast 
milk would be extremely small in a woman receiving 30 mg 
of prednisolone daily (30). Similarly, Öst and coworkers 
examined prednisolone excretion in milk in 6 lactating 
women receiving daily prednisolone doses ranging from 10 
to 80 mg and concluded that even at a daily dose of 80 mg 
prednisolone, the infant would ingest <0.1% of that dose 
(31). These early studies indicate that the physiological 
dose of glucocorticoid required to substitute AI is unlikely 
to cause harm in breast-fed children.
Key points
In summary, there are a number of pathophysiological 
consequences of AI that can directly or indirectly affect 
pregnancy and complicate medical care of these patients. 
Overall, one can expect good maternal and fetal outcomes 
in properly treated patients with AI, which should 
reassure affected patients. However, the high proportion 
of reported adrenal crisis provides clear evidence that 
these patients require good education of their disease and 
close monitoring in specialized centers.
A new diagnosis of AI during pregnancy poses 
challenges due to the rarity of the disease, overlapping 
symptoms with normal pregnancy and difficulties 
in establishing biochemical diagnosis in mild cases. 
Consultation of an endocrinologist in a patient presenting 
with suggestive symptoms of AI should help in early 
diagnosis and management.
Clearly, many questions remain unanswered because 
of the lack of prospective data. Given the rarity of AI, we 
suggest collection of prospective information in pregnant 
patients as part of international registries.
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